A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT00081614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the study is to assess the potential benefit of combining two targeted therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor). The goal will be to determine whether the addition of Erlotinib to Avastin will improve the benefit in metastatic renal cell carcinoma (RCC) with regard to time to progression, response rate, duration of response, and survival compared with Avastin alone. Since Avastin has been shown to be active in renal cancer, the goal will be to assess whether this activity can be enhanced with Erlotinib.
Study identification
- NCT ID
- NCT00081614
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2004 (Type not available)
- Primary completion
- Not listed
- Completion
- Jul 2005 (Actual)
- Last update posted
- May 16, 2014
2004 – 2005
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bay Area Cancer Research Group | Concord | California | 94520 | — |
| UCLA School of Medicine | Los Angeles | California | 90095 | — |
| Kaiser Permanente Medical Group | San Diego | California | 92120 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| UCHSC - Urologic Oncology | Aurora | Colorado | 80010 | — |
| Bennett Cancer Center | Stamford | Connecticut | 06902 | — |
| Lynn Regional Cancer Center - West | Boca Raton | Florida | 33428 | — |
| Ochsner Cancer Institute | New Orleans | Louisiana | 70121 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Wayne State University / Harper University Hospital | Detroit | Michigan | 48201 | — |
| St. Joseph Oncology | Saint Joseph | Missouri | 64507 | — |
| The Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| North Shore University Hospital | Manhasset | New York | 11030 | — |
| NYU School of Medicine | New York | New York | 10016 | — |
| Our Lady of Mercy Medical Center | The Bronx | New York | 10466 | — |
| Northwestern Carolina Oncology & Hematology | Hickory | North Carolina | 28601 | — |
| Raleigh Hematology Oncology | Raleigh | North Carolina | 27609 | — |
| The Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19004 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00081614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2014 · Synced Oct 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00081614 live on ClinicalTrials.gov.